{"id":"https://openalex.org/W2979013135","doi":"https://doi.org/10.1016/j.clml.2019.09.601","title":"Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study","display_name":"Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study","publication_year":2019,"publication_date":"2019-09-30","ids":{"openalex":"https://openalex.org/W2979013135","doi":"https://doi.org/10.1016/j.clml.2019.09.601","mag":"2979013135","pmid":"https://pubmed.ncbi.nlm.nih.gov/32063527","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8895348"},"language":"en","primary_location":{"id":"doi:10.1016/j.clml.2019.09.601","doi":"https://doi.org/10.1016/j.clml.2019.09.601","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clml.2019.09.601","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.clml.2019.09.601","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042176968","display_name":"Michael Richard Grunwald","orcid":"https://orcid.org/0000-0001-5407-9875","observed_orcids":["https://orcid.org/0000-0001-5407-9875"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael R. Grunwald","raw_affiliation_strings":["Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC. Electronic address: michael.grunwald@atriumhealth.org","Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC. Electronic address: michael.grunwald@atriumhealth.org","institution_ids":["https://openalex.org/I4210100342"]},{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027588079","display_name":"David J. Kuter","orcid":"https://orcid.org/0000-0003-2084-8810","observed_orcids":["https://orcid.org/0000-0003-2084-8810","https://orcid.org/0000-0002-7855-2409"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David J. Kuter","raw_affiliation_strings":["Center for Hematology, Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Hematology, Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012856380","display_name":"Ivy P. Altomare","orcid":"https://orcid.org/0000-0002-1222-885X","observed_orcids":["https://orcid.org/0000-0002-1222-885X"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ivy Altomare","raw_affiliation_strings":["Duke Cancer Network, Duke University Medical Center, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke Cancer Network, Duke University Medical Center, Durham, NC","institution_ids":["https://openalex.org/I4210126298","https://openalex.org/I4390039326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061916244","display_name":"John M. Burke","orcid":"https://orcid.org/0000-0002-5144-6710","observed_orcids":["https://orcid.org/0000-0002-5144-6710"]},"institutions":[{"id":"https://openalex.org/I4210140702","display_name":"Rocky Mountain Cancer Centers","ror":"https://ror.org/03ynhs115","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210140702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John M. Burke","raw_affiliation_strings":["US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO","institution_ids":["https://openalex.org/I4210140702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014139712","display_name":"Mark Andrew Walshauser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121884","display_name":"Cancer Care Specialists of Illinois","ror":"https://ror.org/02h8c3526","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210121884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. Walshauser","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Cancer Care Specialists of Illinois, Swansea, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Cancer Care Specialists of Illinois, Swansea, IL","institution_ids":["https://openalex.org/I4210121884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R. Savona","raw_affiliation_strings":["Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022887326","display_name":"Brady Lee Stein","orcid":"https://orcid.org/0000-0002-9713-5299","observed_orcids":["https://orcid.org/0000-0002-9713-5299"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brady Stein","raw_affiliation_strings":["Department of Hematology and Oncology, Northwestern University, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Oncology, Northwestern University, Chicago, IL","institution_ids":["https://openalex.org/I111979921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002632381","display_name":"Stephen T. Oh","orcid":"https://orcid.org/0000-0002-8564-5400","observed_orcids":["https://orcid.org/0000-0002-8564-5400","https://orcid.org/0000-0002-7330-0106"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen T. Oh","raw_affiliation_strings":["Department of Medicine, Washington University School of Medicine, St. Louis, MO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Washington University School of Medicine, St. Louis, MO","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075641618","display_name":"Philomena M. Colucci","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philomena Colucci","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039013983","display_name":"Shreekant V. Parasuraman","orcid":"https://orcid.org/0000-0001-8162-8171","observed_orcids":["https://orcid.org/0000-0001-8162-8171"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shreekant Parasuraman","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091492816","display_name":"Dilan Chamikara Paranagama","orcid":"https://orcid.org/0000-0001-6162-1992","observed_orcids":["https://orcid.org/0000-0001-6162-1992"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dilan Paranagama","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben Mesa","raw_affiliation_strings":["Department of Hematology and Oncology, The University of Texas Health Science Center, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Oncology, The University of Texas Health Science Center, San Antonio, TX","institution_ids":["https://openalex.org/I165951966"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":13,"corresponding_author_ids":["https://openalex.org/A5042176968"],"corresponding_institution_ids":["https://openalex.org/I4210100342"],"apc_list":{"value":1900,"currency":"USD","value_usd":1900},"apc_paid":{"value":1900,"currency":"USD","value_usd":1900},"fwci":1.3732,"has_fulltext":true,"cited_by_count":31,"citation_normalized_percentile":{"value":0.7965709,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"20","issue":"4","first_page":"219","last_page":"225"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/polycythemia-vera","display_name":"polycythemia vera","score":1.0},{"id":"https://openalex.org/keywords/hydroxyurea","display_name":"hydroxyurea","score":1.0},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.9319999814033508},{"id":"https://openalex.org/keywords/dose-titration","display_name":"dose titration","score":0.652999997138977},{"id":"https://openalex.org/keywords/dose-interruption","display_name":"dose interruption","score":0.45500001311302185},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.75},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.671999990940094},{"id":"https://openalex.org/keywords/hematocrit","display_name":"hematocrit","score":0.6610000133514404},{"id":"https://openalex.org/keywords/phlebotomy","display_name":"phlebotomy","score":0.8949999809265137},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.8009999990463257},{"id":"https://openalex.org/keywords/cytoreduction","display_name":"cytoreduction","score":0.6980000138282776}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9609730243682861},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.9236171245574951},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4905783236026764},{"id":"https://openalex.org/C2910079294","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia rubra vera","level":3,"score":0.4254648983478546}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001772","descriptor_name":"Blood Cell Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008137","descriptor_name":"Longitudinal Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011087","descriptor_name":"Polycythemia Vera","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D011087","descriptor_name":"Polycythemia Vera","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.clml.2019.09.601","doi":"https://doi.org/10.1016/j.clml.2019.09.601","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clml.2019.09.601","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},{"id":"pmid:32063527","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32063527","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical lymphoma, myeloma & leukemia","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8895348","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8895348","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Clin Lymphoma Myeloma Leuk","raw_type":"Text"},{"id":"pmh:oai:digitalcommons.wustl.edu:open_access_pubs-10260","doi":null,"is_oa":true,"landing_page_url":"https://digitalcommons.wustl.edu/open_access_pubs/9256","pdf_url":"https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article=10260&context=open_access_pubs","source":{"id":"https://openalex.org/S4306400764","display_name":"Digital Commons@Becker (Washington University School of Medicine)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I204465549","host_organization_name":"Washington University in St. Louis","host_organization_lineage":["https://openalex.org/I204465549"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Open Access Publications","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1016/j.clml.2019.09.601","doi":"https://doi.org/10.1016/j.clml.2019.09.601","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clml.2019.09.601","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1221135887","display_name":"Mays Cancer Center at UT Health SA","funder_award_id":"P30CA054174","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307776","display_name":"Merck","ror":"https://ror.org/02891sr49"},{"id":"https://openalex.org/F4320307778","display_name":"Novartis","ror":"https://ror.org/02f9zrr09"},{"id":"https://openalex.org/F4320307779","display_name":"Roche","ror":"https://ror.org/00by1q217"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320309052","display_name":"Alexion Pharmaceuticals","ror":"https://ror.org/031ywxc85"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320313971","display_name":"TG Therapeutics","ror":"https://ror.org/00pwykz63"},{"id":"https://openalex.org/F4320314605","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38"},{"id":"https://openalex.org/F4320315663","display_name":"Sunesis","ror":"https://ror.org/0187pm092"},{"id":"https://openalex.org/F4320316629","display_name":"Agios Pharmaceuticals","ror":"https://ror.org/002x06r10"},{"id":"https://openalex.org/F4320317076","display_name":"Zafgen","ror":"https://ror.org/05035d657"},{"id":"https://openalex.org/F4320317479","display_name":"CTI Biopharma","ror":"https://ror.org/017bk0e71"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320318324","display_name":"Cardinal Health","ror":"https://ror.org/03pd82777"},{"id":"https://openalex.org/F4320318412","display_name":"Argenx","ror":"https://ror.org/04spfxf63"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320334790","display_name":"Daiichi Sankyo Company","ror":"https://ror.org/027y26122"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337449","display_name":"Janssen Biotech","ror":"https://ror.org/03qd7mz70"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W266774159","https://openalex.org/W942930643","https://openalex.org/W1446966563","https://openalex.org/W1603401075","https://openalex.org/W1959044271","https://openalex.org/W1968468753","https://openalex.org/W1979832242","https://openalex.org/W1980972742","https://openalex.org/W1984960437","https://openalex.org/W1998721150","https://openalex.org/W2068493370","https://openalex.org/W2072881492","https://openalex.org/W2086511628","https://openalex.org/W2112316414","https://openalex.org/W2122395736","https://openalex.org/W2153170459","https://openalex.org/W2158669800","https://openalex.org/W2217750424","https://openalex.org/W2524206846","https://openalex.org/W2570291199","https://openalex.org/W2735582214","https://openalex.org/W2744846745","https://openalex.org/W2790003237","https://openalex.org/W3083023403"],"related_works":["https://openalex.org/W2933301766","https://openalex.org/W2910874709","https://openalex.org/W2292080378","https://openalex.org/W2979919855","https://openalex.org/W6939680801","https://openalex.org/W6902279733","https://openalex.org/W4405038586","https://openalex.org/W4296533249","https://openalex.org/W3094901612","https://openalex.org/W4386277427"],"abstract_inverted_index":{"BACKGROUND:":[0],"Polycythemia":[1],"vera":[2],"(PV)":[3],"is":[4,44],"associated":[5],"with":[6,33,69,228,230],"increased":[7],"blood":[8,237],"cell":[9],"counts,":[10],"risk":[11],"of":[12,25,67,94,147,179,217,226,246],"thrombosis,":[13],"and":[14,18,62,81,133,156,168,174,177,182,209,244],"symptoms":[15,245],"including":[16],"fatigue":[17],"pruritus.":[19],"National":[20],"guidelines":[21],"support":[22],"the":[23,72,92,102,112,221],"use":[24],"hydroxyurea":[26],"(HU)":[27],"in":[28,71],"high-risk":[29],"patients":[30,68,104,148,227],"or":[31,97],"those":[32,186],"some":[34],"other":[35],"clinical":[36,58],"indication":[37],"for":[38,108,165,190,223,242],"cytoreduction.":[39],"PATIENTS":[40],"AND":[41],"METHODS:":[42],"REVEAL":[43],"a":[45],"prospective,":[46],"observational":[47],"study":[48],"designed":[49],"to":[50,54,89,91,206,235],"collect":[51],"data":[52,98],"pertaining":[53],"demographics,":[55],"disease":[56],"burden,":[57],"management,":[59],"patient-reported":[60],"outcomes,":[61],"health":[63],"care":[64],"resource":[65],"utilization":[66],"PV":[70,229],"United":[73],"States.":[74],"In":[75],"this":[76,218],"analysis,":[77],"HU":[78,107,114,127,166,189,232,247],"treatment":[79],"patterns":[80],"outcomes":[82],"were":[83,129,170],"assessed":[84],"from":[85],"6":[86],"months":[87,118],"prior":[88],"enrollment":[90],"time":[93],"discontinuation,":[95],"death,":[96],"cutoff.":[99],"RESULTS:":[100],"Of":[101,185],"1381":[103],"who":[105,187],"received":[106,139,188],"\u2265":[109,140,191,201],"3":[110,192],"months,":[111,193],"median":[113],"exposure":[115],"was":[116],"23.6":[117],"(range,":[119],"3.1-38.5":[120],"months).":[121],"The":[122,161,215],"most":[123,162],"common":[124,163],"maximum":[125],"daily":[126],"doses":[128],"1000":[130],"mg":[131,135],"(30.6%)":[132],"500":[134],"(30.1%);":[136],"only":[137],"6.4%":[138],"2":[141],"g/d":[142],"HU.":[143,160],"Approximately":[144],"one-third":[145],"(32.3%)":[146],"had":[149,153,195,211],"dose":[150,154,233],"adjustments,":[151],"23.8%":[152],"interruptions,":[155],"257":[157],"(18.6%)":[158],"discontinued":[159],"reasons":[164],"discontinuations":[167],"interruptions":[169],"adverse":[171],"events/intolerance":[172],"(37.1%":[173],"54.5%,":[175],"respectively)":[176],"lack":[178],"efficacy":[180],"(35.5%":[181],"22.1%,":[183],"respectively).":[184],"57.1%":[194],"hematocrit":[196],"values":[197],">":[198],"45%":[199],"on":[200],"1":[202],"occasion,":[203],"33.1%":[204],"continued":[205],"receive":[207],"phlebotomies,":[208],"27.4%":[210],"uncontrolled":[212],"myeloproliferation.":[213],"CONCLUSION:":[214],"results":[216],"analysis":[219],"emphasize":[220],"need":[222],"active":[224],"management":[225],"appropriate":[231],"titration":[234],"maintain":[236],"count":[238],"control":[239],"while":[240],"monitoring":[241],"signs":[243],"intolerance.":[248]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2019-10-10T00:00:00"}